Collegium cuts 2026 revenue guidance on weaker Nucynta generic pricing
Collegium posted 6% revenue growth in Q2 2026, but lowered full-year product revenue and adjusted EBITDA guidance due to Nucynta authorized generic pricing.
SEC filing
Latest
2 stories